Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
ALLMERCAP mercaptopurine monohydrate 20 mg/mL oral liquid suspension bottle, Link Medical Products Pty Ltd T A Link Pharmaceuticals, CON-1130
Product name
ALLMERCAP mercaptopurine monohydrate 20 mg/mL oral liquid suspension bottle
Sponsor name
Link Medical Products Pty Ltd T A Link Pharmaceuticals
Batches
All batches supplied from 13 July 2023 until 29 February 2024
Consent start
Consent no.
CON-1130
Standard
Paragraphs 8(1)(a) and 9(1)(a), Paragraphs 8(1)(b) and 9(1)(b), Subparagraph 8(1)(j)(iv)(A), Paragraph 9(3)(a), Paragraph 8(1)(i), Paragraph 10(4)(j), Subsection 11(5). of Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines
Non-compliance with standard
The product(s) will be supplied in the UK approved packaging which has the
following differences: the name Xaluprine in place of Allmercap; the active
ingredient name is referred to as mercaptopurine instead of mecaptopurine
monohydrate; the name and quantity of the active ingredient are not in a
cohesive unit with the name of the medicine; the storage statement is not in the
permitted format; the Schedule 1 substances aspartame and potassium sorbate are
not expressed as required; the sponsors name and address are not included on the
label and the name of the sponsor is not included on the bottle label
Conditions imposed
1. A 'Dear Healthcare Provider' letter identical to that provided to the
Therapeutic Goods Administration on 7 July 2023 will be supplied with each
affected batch describing the differences in the labels.
2. Sponsor details will be attached to the labels in such away as to not impact
any other relevant information on the labels.
Therapeutic product type
Prescription medicines